- Home
- ERH vs CRVO Comparison
ERH vs CRVO Comparison
Compare ERH & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERH
- CRVO
- Stock Information
- Founded
- ERH 2004
- CRVO 2001
- Country
- ERH United States
- CRVO United States
- Employees
- ERH N/A
- CRVO N/A
- Industry
- ERH Finance/Investors Services
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ERH Finance
- CRVO Health Care
- Exchange
- ERH Nasdaq
- CRVO Nasdaq
- Market Cap
- ERH 97.6M
- CRVO 95.4M
- IPO Year
- ERH N/A
- CRVO N/A
- Fundamental
- Price
- ERH $10.58
- CRVO $8.80
- Analyst Decision
- ERH
- CRVO Strong Buy
- Analyst Count
- ERH 0
- CRVO 8
- Target Price
- ERH N/A
- CRVO $25.43
- AVG Volume (30 Days)
- ERH 23.2K
- CRVO 1.0M
- Earning Date
- ERH 01-01-0001
- CRVO 05-13-2025
- Dividend Yield
- ERH 8.85%
- CRVO N/A
- EPS Growth
- ERH N/A
- CRVO N/A
- EPS
- ERH N/A
- CRVO N/A
- Revenue
- ERH N/A
- CRVO $9,737,974.00
- Revenue This Year
- ERH N/A
- CRVO N/A
- Revenue Next Year
- ERH N/A
- CRVO N/A
- P/E Ratio
- ERH N/A
- CRVO N/A
- Revenue Growth
- ERH N/A
- CRVO 36.29
- 52 Week Low
- ERH $7.97
- CRVO $1.80
- 52 Week High
- ERH $10.91
- CRVO $25.69
- Technical
- Relative Strength Index (RSI)
- ERH 48.39
- CRVO 50.69
- Support Level
- ERH $10.26
- CRVO $9.03
- Resistance Level
- ERH $10.70
- CRVO $10.40
- Average True Range (ATR)
- ERH 0.27
- CRVO 1.75
- MACD
- ERH 0.01
- CRVO -0.32
- Stochastic Oscillator
- ERH 51.28
- CRVO 16.26
About ERH Allspring Utilities and High Income Fund
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.